0
Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
0 Vote
1 Contributor
2102 Views 
0 Saved
0 Vote 1 Contributor2102 Views 0 SavedYou might also be interested in
Cancer is by definition abnormal growth of tissue which spreads and causes damage. The actual mechanism why and how it happens is the subject of a great deal of study but appears to involve small groups of cancer cells invading and breaking off in blood and lymph vessels and being carried along to d....
Hello, please describe your problem in detail, then only we'll be able to provide you treatment costs. You can call us on +91-8010994994 and talk to our medical expert.
Fortis Hospital is one of the best cancer hospitals in Bangalore and has facilities for paediatric and adult oncology in India. Cost of breast cancer treatment varies from hospitals to hospital and person to person depending on the person condition, surgeon, number of therapies, lab examination....
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.